RhumbLine Advisers’s Immuneering IMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$271K Buy
66,086
+172
+0.3% +$813 ﹤0.01% 3100
2026
Q2
$329K Buy
+65,914
New +$333K ﹤0.01% 3011
2024
Q3
– Sell
-3,386
Closed -$4.33K – 4261
2024
Q2
$4.33K Sell
3,386
-17,546
-84% -$28.8K ﹤0.01% 4106
2024
Q1
$60.5K Buy
20,932
+909
+5% +$5.09K ﹤0.01% 3584
2023
Q4
$147K Buy
20,023
+217
+1% +$1.45K ﹤0.01% 3321
2023
Q3
$152K Buy
19,806
+2,275
+13% +$20.9K ﹤0.01% 3302
2023
Q2
$178K Buy
+17,531
New +$169K ﹤0.01% 3297
2022
Q2
– Sell
-13,819
Closed -$89K – 3164
2022
Q1
$89K Buy
+13,819
New +$133K ﹤0.01% 2907

Other funds holding IMRX

RhumbLine Advisers's IMRX Position: Q3 2026 in Review

RhumbLine Advisers increased its Immuneering (IMRX) stake by 0.26% in Q3 2026, buying an estimated $813 and bringing the position to 66,086 shares worth $271K. The position accounts for ﹤0.01% of the portfolio, ranked #3100.

RhumbLine Advisers first reported a position in IMRX in Q1 2022 and has held it in 8 quarters since. The position peaked at $329K in Q2 2026. 131 funds tracked by Wall St. Rank hold IMRX as of Q3 2026.

  • RhumbLine Advisers held 66,086 shares of Immuneering worth $271K as of Q3 2026.
  • RhumbLine Advisers bought 172 Immuneering shares in Q3 2026, an estimated $813.
  • Immuneering made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3100 holding.
  • RhumbLine Advisers first reported a position in Immuneering in Q1 2022 and has held it in 8 quarters since.
  • RhumbLine Advisers's Immuneering position peaked at $329K in Q2 2026.
  • 131 funds tracked by Wall St. Rank held Immuneering as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.